| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615563 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 5 Pages |
Abstract
After a median follow-up of 8 years, imatinib was found to induce long survival with manageable side effect in adult Saudi patients with CML-CP.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Ali M. Al-Amri,